Viatris (VTRS) Total Liabilities (2019 - 2026)
Viatris (VTRS) posted Total Liabilities of $20.8 billion for Q2 2026, down 6.28% on a QoQ basis from $22.2 billion in Q1 2026, and down 9.0% year-over-year from $22.8 billion in Q2 2025.
Analysis
Viatris (VTRS) Total Liabilities (2019 - 2026) Analysis & Trends
Viatris has reported Total Liabilities for 8 years, with the latest figure at $20.8 billion in Q2 2026.
- On a quarterly basis, Total Liabilities fell 9.0% year-over-year to $20.8 billion in Q2 2026; TTM through Jun 2026 was $20.8 billion, a 9.0% decrease from a year earlier, with the FY2025 full-year figure at $22.5 billion, down 1.68% from the prior year.
- Total Liabilities was $20.8 billion for Q2 2026 at Viatris, down from $22.2 billion in the prior quarter.
- The five-year high for Total Liabilities was $33.0 billion in Q1 2022, with the low at $20.8 billion in Q2 2026.
- Average Total Liabilities over 5 years is $26.0 billion, with a median of $26.5 billion recorded in 2023.
- The largest YoY upside for Total Liabilities was 1.68% in 2025 against a maximum downside of 16.48% in 2025.
- Over 5 years, Total Liabilities stood at $28.9 billion in 2022, then dropped by 5.98% to $27.2 billion in 2023, then declined by 15.99% to $22.9 billion in 2024, then slipped by 1.68% to $22.5 billion in 2025, then slipped by 7.55% to $20.8 billion in 2026.
- The last three Total Liabilities figures came in at $20.8 billion (Q2 2026), $22.2 billion (Q1 2026), and $22.5 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 32.10 Bn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 20.78 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 1.99 Bn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 3.74 Bn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 25.60 Bn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 1.78 Bn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 896.90 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 975.61 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 33.31 Mn |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | 21.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.78 Bn |
| Mar 31, 2026 | 22.18 Bn |
| Dec 31, 2025 | 22.48 Bn |
| Sep 30, 2025 | 22.70 Bn |
| Jun 30, 2025 | 22.84 Bn |
| Mar 31, 2025 | 22.82 Bn |
| Dec 31, 2024 | 22.87 Bn |
| Sep 30, 2024 | 24.96 Bn |
| Jun 30, 2024 | 25.81 Bn |
| Mar 31, 2024 | 27.33 Bn |
| Dec 31, 2023 | 27.22 Bn |
| Sep 30, 2023 | 27.88 Bn |
| Jun 30, 2023 | 27.85 Bn |
| Mar 31, 2023 | 28.36 Bn |
| Dec 31, 2022 | 28.95 Bn |
| Sep 30, 2022 | 29.48 Bn |
| Jun 30, 2022 | 31.32 Bn |
| Mar 31, 2022 | 33.02 Bn |
| Dec 31, 2021 | 34.35 Bn |
| Sep 30, 2021 | 34.93 Bn |